BlueRock Therapeutics

1 week ago | globenewswire.com | BlueRock Therapeutics |Jeff Lockwood

Cambridge, MA USA, April 16, 2025 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today announced the publication of the 18-month data from its Phase 1 exPDite clinical trial for bemdaneprocel in the journal Nature.

Jan 13, 2025 | bluerocktx.com | BlueRock Therapeutics

Phase III exPDite-2 trial follows completion and discussion of Phase I trial data with US FDA under Regenerative Medicine Advanced Therapy (RMAT) designation exPDite-2 is a randomized, sham surgery-controlled double-blind trial assessing efficacy and safety of bemdaneprocel in people living with moderate Parkinson’s disease Expected to be initiated in H1 2025, exPDite-2 is the first registrational Phase III clinical trial for an investigational allogeneic pluripotent stem cell derived therapy...

Sep 27, 2024 | bluerocktx.com | BlueRock Therapeutics

Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating individuals living with Parkinson’s disease At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts Secondary clinical endpoints continue to suggest positive trends from baseline through the duration of follow-up, with more encouraging trends in the high dose cohort than those in the low dose...

Sep 3, 2024 | globenewswire.com | BlueRock Therapeutics |Jeff Lockwood

Cambridge, MA USA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary photoreceptor diseases.

May 30, 2024 | globenewswire.com | BlueRock Therapeutics |Jeff Lockwood

Berlin, Germany and Cambridge, MA, USA, May 30, 2024 (GLOBE NEWSWIRE) -- Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today that BlueRock’s investigational cell therapy bemdaneprocel for the treatment of Parkinson’s disease has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA).